Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Infections Post Transplant

Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan

Bone Marrow Transplantation volume 27, pages 437–444 (2001)Cite this article

Abstract

From April 1998 to March 2000, a cytomegalovirus (CMV) antigenemia-guided pre-emptive approach for CMV disease was evaluated in 77 adult patients who received allogeneic hematopoietic stem cell transplantation at the National Cancer Center Hospital. A CMV antigenemia assay was performed at least once a week after engraftment. High-level antigenemia was defined as a positive result with 10 or more positive cells per 50 000 cells and low-level antigenemia was defined as less than 10 positive cells. Among the 74 patients with initial engraftment, 51 developed positive antigenemia. Transplantation from alternative donors and the development of grade II–IV GVHD were independent risk factors for positive antigenemia. Ganciclovir was administered as pre-emptive therapy in 39 patients in a risk-adapted manner. None of the nine low-risk patients with low-level antigenemia as their initial positive result developed high-level antigenemia even though ganciclovir was withheld. Only one patient developed early CMV disease (hepatitis) during the study period. CMV antigenemia resolved in all but two cases, in whom ganciclovir was replaced with foscarnet. In eight patients, however, the neutrophil count decreased to 0.5 × 109/l or less after starting ganciclovir, including three with documented infections and two with subsequent secondary graft failure. The total amount of ganciclovir and possibly the duration of high-dose ganciclovir might affect the incidence of neutropenia. We concluded that antigenemia-guided pre-emptive therapy with a decreased dose of ganciclovir and response-oriented dose adjustment might be appropriate to decrease the toxicity of ganciclovir without increasing the risk of CMV disease. Bone Marrow Transplantation (2001) 27, 437–444.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Forman SJ, Zaia JA . Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? Blood 1994 83: 2392–2398

    CAS  PubMed  Google Scholar 

  2. Goodrich JM, Bowden R, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant Ann Intern Med 1993 118: 173–178

    Article  CAS  PubMed  Google Scholar 

  3. Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients Ann Intern Med 1993 118: 179–184

    Article  CAS  PubMed  Google Scholar 

  4. Schmidt GM, Horak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope–Stanford–Syntex CMV Study Group New Engl J Med 1991 324: 1005–1011

    Article  CAS  PubMed  Google Scholar 

  5. Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation Blood 1995 86: 2815–2820

    CAS  PubMed  Google Scholar 

  6. Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study Blood 1996 88: 4063–4071

    CAS  PubMed  Google Scholar 

  7. van der Bij W, Torensma R, van Son WJ et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes J Med Virol 1988 25: 179–188

    Article  CAS  PubMed  Google Scholar 

  8. Gondo H, Minematsu T, Harada M et al. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation Br J Haematol 1994 86: 130–137

    Article  CAS  PubMed  Google Scholar 

  9. Takenaka K, Gondo H, Tanimoto K et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group Bone Marrow Transplant 1997 19: 241–248

    Article  CAS  PubMed  Google Scholar 

  10. Verdonck LF, Dekker AW, Rozenberg-Arska M, van den Hoek MR . A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants Clin Infect Dis 1997 24: 901–907

    Article  CAS  PubMed  Google Scholar 

  11. Koehler M, St George K, Ehrlich GD et al. Prevention of CMV disease in allogeneic BMT recipients by cytomegalovirus antigenemia-guided preemptive ganciclovir therapy J Pediatr Hematol Oncol 1997 19: 43–47

    Article  CAS  PubMed  Google Scholar 

  12. Manteiga R, Martino R, Sureda A et al. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience Bone Marrow Transplant 1998 22: 899–904

    Article  CAS  PubMed  Google Scholar 

  13. Kanda Y, Chiba S, Suzuki T et al. Time course analysis of semi-quantitative PCR and antigenaemia assay for prevention of cytomegalovirus disease after bone marrow transplantation Br J Haematol 1998 100: 222–225

    Article  CAS  PubMed  Google Scholar 

  14. Boeckh M, Bowden RA, Gooley T et al. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients Blood 1999 93: 1781–1782

    CAS  PubMed  Google Scholar 

  15. Mori T, Okamoto S, Matsuoka S et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation Bone Marrow Transplant 2000 25: 765–769

    Article  CAS  PubMed  Google Scholar 

  16. Shimokawa T, Morishima Y, Kitaori K et al. Early treatment of CMV antigenemia with ganciclovir for prevention of fatal CMV disease in patients receiving marrow from HLA-matched unrelated donors Int J Hematol 1999 70: 119–126

    CAS  PubMed  Google Scholar 

  17. Morishima Y, Morishita Y, Tanimoto M et al. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group Blood 1989 74: 2252–2256

    CAS  PubMed  Google Scholar 

  18. Morishima Y, Kodera Y, Hirabayashi N et al. Low incidence of acute GVHD in patients transplanted with marrow from HLA-A,B,DR-compatible unrelated donors among Japanese Bone Marrow Transplant 1995 15: 235–239

    CAS  PubMed  Google Scholar 

  19. Goodrich JM, Boeckh M, Bowden R . Strategies for the prevention of cytomegalovirus disease after marrow transplantation Clin Infect Dis 1994 19: 287–298

    Article  CAS  PubMed  Google Scholar 

  20. Boeckh M, Woogerd PM, Stevens-Ayers T et al. Factors influencing detection of quantitative cytomegalovirus antigenemia J Clin Microbiol 1994 32: 832–834

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Perez JL, Niubo J, Ardanuy C et al. Comparison of three commercially available monoclonal antibodies directed against pp65 antigen for cytomegalovirus antigenemia assay Diagn Microbiol Infect Dis 1995 21: 21–25

    Article  CAS  PubMed  Google Scholar 

  22. St George K, Rinaldo CR Jr . Comparison of commercially available antibody reagents for the cytomegalovirus pp65 antigenemia assay Clin Diagn Virol 1997 7: 147–152

    Article  CAS  PubMed  Google Scholar 

  23. Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation New Engl J Med 1991 325: 1601–1607

    Article  CAS  PubMed  Google Scholar 

  24. Boeckh M, Bowden RA, Goodrich JM et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation Blood 1992 80: 1358–1364

    CAS  PubMed  Google Scholar 

  25. Wakui M, Okamoto S, Ishida A et al. Prospective evaluation for upper gastrointestinal tract acute graft-versus-host disease after hematopoietic stem cell transplantation Bone Marrow Transplant 1999 23: 573–578

    Article  CAS  PubMed  Google Scholar 

  26. Bass EB, Powe NR, Goodman SN et al. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis Bone Marrow Transplant 1993 12: 273–282

    CAS  PubMed  Google Scholar 

  27. Messori A, Rampazzo R, Scroccaro G, Martini N . Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta-analysis Bone Marrow Transplant 1994 13: 163–167

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stem Cell Transplant Unit, National Cancer Center Hospital, Tokyo, Japan

    Y Kanda, S Mineishi, T Saito, S Seo, A Saito, K Suenaga, M Ohnishi, H Niiya, K Nakai, T Takeuchi, N Kawahigashi, N Shoji, T Ogasawara, R Tanosaki & Y Takaue

  2. Hematology Division, National Cancer Center Hospital, Tokyo, Japan

    Y Kobayashi & K Tobinai

  3. Department of Hematology, Toranomon Hospital, Nagoya, Japan

    M Kami

  4. Hematology Division, Tokyo Metropolitan Komagome Hospital, Nagoya, Japan

    S Mori

  5. Laboratory of Chemotherapy, Aichi Cancer Center, Nagoya, Japan

    R Suzuki

  6. Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

    H Kunitoh

Authors
  1. Y Kanda
    View author publications

    Search author on:PubMed Google Scholar

  2. S Mineishi
    View author publications

    Search author on:PubMed Google Scholar

  3. T Saito
    View author publications

    Search author on:PubMed Google Scholar

  4. S Seo
    View author publications

    Search author on:PubMed Google Scholar

  5. A Saito
    View author publications

    Search author on:PubMed Google Scholar

  6. K Suenaga
    View author publications

    Search author on:PubMed Google Scholar

  7. M Ohnishi
    View author publications

    Search author on:PubMed Google Scholar

  8. H Niiya
    View author publications

    Search author on:PubMed Google Scholar

  9. K Nakai
    View author publications

    Search author on:PubMed Google Scholar

  10. T Takeuchi
    View author publications

    Search author on:PubMed Google Scholar

  11. N Kawahigashi
    View author publications

    Search author on:PubMed Google Scholar

  12. N Shoji
    View author publications

    Search author on:PubMed Google Scholar

  13. T Ogasawara
    View author publications

    Search author on:PubMed Google Scholar

  14. R Tanosaki
    View author publications

    Search author on:PubMed Google Scholar

  15. Y Kobayashi
    View author publications

    Search author on:PubMed Google Scholar

  16. K Tobinai
    View author publications

    Search author on:PubMed Google Scholar

  17. M Kami
    View author publications

    Search author on:PubMed Google Scholar

  18. S Mori
    View author publications

    Search author on:PubMed Google Scholar

  19. R Suzuki
    View author publications

    Search author on:PubMed Google Scholar

  20. H Kunitoh
    View author publications

    Search author on:PubMed Google Scholar

  21. Y Takaue
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kanda, Y., Mineishi, S., Saito, T. et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant 27, 437–444 (2001). https://doi.org/10.1038/sj.bmt.1702805

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702805

Keywords

This article is cited by

Search

Advanced search

Quick links